WO1998005331A3 - Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators - Google Patents

Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators Download PDF

Info

Publication number
WO1998005331A3
WO1998005331A3 PCT/US1997/013605 US9713605W WO9805331A3 WO 1998005331 A3 WO1998005331 A3 WO 1998005331A3 US 9713605 W US9713605 W US 9713605W WO 9805331 A3 WO9805331 A3 WO 9805331A3
Authority
WO
WIPO (PCT)
Prior art keywords
agonist
diabetes
prevention
treatment
cardiovascular disease
Prior art date
Application number
PCT/US1997/013605
Other languages
French (fr)
Other versions
WO1998005331A2 (en
Inventor
James R Paterniti
Michael R Briggs
Ranjan Mukherjee
Johan Auwerx
Bart Stael
Original Assignee
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc
Priority to EP97938101A priority Critical patent/EP0930882A2/en
Priority to AU40507/97A priority patent/AU4050797A/en
Publication of WO1998005331A2 publication Critical patent/WO1998005331A2/en
Publication of WO1998005331A3 publication Critical patent/WO1998005331A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins

Abstract

This invention relates to methods and compositions for the prevention and treatment of Type 2 diabetes and cardiovascular disease with diabetic or pre-diabetic conditions or symptoms associated therewith using both a PPARη agonist and a PPARα agonist or a compound which activates both PPARη and PPARα. A preferred PPARη agonist is a thiazolidinedione compound, including BRL 49653, troglitazone, pioglitazone, ciglitazone, WAY-120,744, englitazone, AD 5075, darglitazone, and congeners, analogs, derivatives and pharmaceutically acceptable salts thereof. A preferred PPARα agonist is a fibrate compound including gemfibrozil, fenofibrate, bezofibrate, clofibrate, ciprofibrate, and analogs, derivatives and pharmaceutically acceptable salts thereof.
PCT/US1997/013605 1996-08-02 1997-08-01 Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators WO1998005331A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP97938101A EP0930882A2 (en) 1996-08-02 1997-08-01 Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
AU40507/97A AU4050797A (en) 1996-08-02 1997-08-01 Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2294996P 1996-08-02 1996-08-02
US60/022,949 1996-08-02

Publications (2)

Publication Number Publication Date
WO1998005331A2 WO1998005331A2 (en) 1998-02-12
WO1998005331A3 true WO1998005331A3 (en) 1998-05-07

Family

ID=21812265

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/013605 WO1998005331A2 (en) 1996-08-02 1997-08-01 Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators

Country Status (3)

Country Link
EP (1) EP0930882A2 (en)
AU (1) AU4050797A (en)
WO (1) WO1998005331A2 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
DE122007000044I2 (en) 1997-01-07 2011-05-05 Amylin Pharmaceuticals Inc USE OF EXEDINES AND THEIR ANTAGONISTS TO REDUCE FOOD CONSUMPTION
FR2774591B1 (en) * 1998-02-12 2000-05-05 Lipha PHARMACEUTICAL COMPOSITION COMPRISING THE ASSOCIATION OF METFORMIN AND FIBRATE AND THE USE THEREOF FOR THE PREPARATION OF MEDICINES FOR REDUCING HYPERGLYCEMIA
EP1428531A1 (en) 1998-05-11 2004-06-16 Takeda Chemical Industries, Ltd. Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
DE19823831A1 (en) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim New pharmaceutical use of isoleucyl thiazolidide and its salts
AU4250200A (en) * 1999-04-19 2000-11-02 Coelacanth Corporation Ppar-(gamma) agonists as agents for the treatment of type ii diabetes
WO2000065091A2 (en) * 1999-04-23 2000-11-02 Curagen Corporation Method of identifying ligands for the peroxisome proliferator activated receptor gamma using differential gene expression
WO2001016120A1 (en) 1999-08-27 2001-03-08 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
WO2001044512A2 (en) * 1999-12-16 2001-06-21 Curagen Corporation Method of identifying ligands for the peroxisome proliferator activated receptor gamma using differential gene expression
ES2227115T5 (en) * 2000-01-10 2014-10-30 Amylin Pharmaceuticals, Inc. Use of exendins and their agonists for the treatment of hypertriglyceridemia
US7151191B2 (en) 2000-01-13 2006-12-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
GB0002667D0 (en) * 2000-02-04 2000-03-29 Glaxo Group Ltd medicamesnts
KR20020081424A (en) * 2000-03-09 2002-10-26 아벤티스 파마 도이칠란트 게엠베하 Therapeutic uses of PPAR mediators
HUP0301146A3 (en) * 2000-04-28 2004-08-30 Sankyo Co 2-chlor-5-nitrophenyl carboxamide derivatives, pharmaceutical compositions containing them and their use
JP2004503499A (en) * 2000-06-16 2004-02-05 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー Treatment and prevention of symptoms associated with cardiac insulin resistance
IT1317885B1 (en) * 2000-08-01 2003-07-15 Sigma Tau Ind Farmaceuti USE OF FIBRATES FOR THE PREPARATION OF A USEFUL DRUG IN THE TREATMENT OF CONGESTIAL HEART INSUFFICIENCY.
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
MXPA03007284A (en) 2001-02-15 2003-12-04 Pfizer Prod Inc Ppar agonists.
WO2002064130A1 (en) * 2001-02-15 2002-08-22 Pfizer Products Inc. Proliferative activator receptor (ppar) compounds
ATE305459T1 (en) 2001-03-28 2005-10-15 Schering Corp METHOD FOR THE ENANTIOSELECTIVE SYNTHESIS OF AZETIDINONE INTERMEDIATE PRODUCTS
DE60237594D1 (en) * 2001-04-25 2010-10-21 Takeda Pharmaceutical USE OF THE ABC EXPRESSION PROMOTOR PIOGLITAZONE FOR THE TREATMENT OF ARTERIOSCLEROSIS OBLITERANS
EP1461069A2 (en) 2001-12-29 2004-09-29 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
ITRM20020014A1 (en) 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti DERIVATIVES OF A-PHENYLTHIOCARBOXYL AND A-PHYLYOXYCARBOXYL ACIDS USEFUL FOR THE TREATMENT OF DISEASES THAT RESPOND TO THE ACTIVATION OF
CA2481371A1 (en) * 2002-03-11 2003-09-18 Peter Zahradka Use of ppar alpha agonists for the treatment of vascular and renal diseases
CN1274305C (en) * 2002-03-25 2006-09-13 罗健 Pharmaceutical composition with combined active agents and methods for using the same
EP1388352A1 (en) * 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
EP1388351A1 (en) * 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Use of fibrate to treat weight gain associated with rosiglitazone treatment
UA83202C2 (en) 2002-11-26 2008-06-25 Пфайзер Продактс Инк. Phenyl substituted piperidine compounds for use as ppar activators
EP1424070A1 (en) * 2002-11-28 2004-06-02 Fournier Laboratories Ireland Limited Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
MX354786B (en) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER and OTHER DISORDERS.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (en) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014057522A1 (en) 2012-10-12 2014-04-17 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2904129A1 (en) 2013-03-15 2014-09-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
CA2913737A1 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
AU2014331812B2 (en) 2013-10-09 2019-01-17 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0305890A2 (en) * 1987-09-01 1989-03-08 Roche Diagnostics GmbH Use of bezafibrate for the treatment of diabetes
JPH05194209A (en) * 1992-01-21 1993-08-03 Grelan Pharmaceut Co Ltd Hemangioendothelial cell function improver
WO1995007694A1 (en) * 1993-09-15 1995-03-23 Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of niddm
WO1995007697A2 (en) * 1993-09-15 1995-03-23 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
WO1997010819A1 (en) * 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Treating niddm with rxr agonists
WO1997025042A1 (en) * 1996-01-09 1997-07-17 Smithkline Beecham P.L.C. Use of an agonist of ppar-alpha and ppar-gamma for the treatment of syndrom x

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0305890A2 (en) * 1987-09-01 1989-03-08 Roche Diagnostics GmbH Use of bezafibrate for the treatment of diabetes
JPH05194209A (en) * 1992-01-21 1993-08-03 Grelan Pharmaceut Co Ltd Hemangioendothelial cell function improver
WO1995007694A1 (en) * 1993-09-15 1995-03-23 Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of niddm
WO1995007697A2 (en) * 1993-09-15 1995-03-23 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
WO1997010819A1 (en) * 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Treating niddm with rxr agonists
WO1997025042A1 (en) * 1996-01-09 1997-07-17 Smithkline Beecham P.L.C. Use of an agonist of ppar-alpha and ppar-gamma for the treatment of syndrom x

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BARNETT ET AL.: "Effect of Clofibrate on Glucose Tolerance in Maturity Onset Diabetes", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, vol. 4, 1977, pages 455 - 458, XP002045778 *
DATABASE WPI Section Ch Week 9335, Derwent World Patents Index; Class B05, AN 93-278192, XP002045779 *
KARAM J H: "TYPE II DIABETES AND SYNDROME X PATHOGENESIS AND GLYCEMIC MANAGEMENT", ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, vol. 21, no. 2, 1 June 1992 (1992-06-01), pages 329 - 350, XP000605976 *
LEHMANN J M ET AL: "AN ANTIDIABETIC THIAZOLIDINEDIONE IS A HIGH AFFINITY LIGAND FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPARGAMMA)", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 22, 2 June 1995 (1995-06-02), pages 12953 - 12956, XP000577082 *
LENHARD J M ET AL: "ANALYSIS OF THIAZOLIDINEDIONE, BIGUANIDE AND RETINOID EFFECTS ON ADIPOGENESIS AND THE NUCLEAR RECEPTORS PPARgamma AND RXR", DIABETOLOGIA, SUPPLEMENT, vol. 39, 5 September 1996 (1996-09-05), pages A234, XP000613679 *
WILLSON T M ET AL: "THE STRUCTURE-ACTIVITY RELATIONSHIP BETWEEN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AGONISM AND THE ANTIHYPERGLYCEMIC ACTIVITY OF THIAZOLIDINEDIONES", JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 3, 2 February 1996 (1996-02-02), pages 665 - 668, XP000613613 *

Also Published As

Publication number Publication date
WO1998005331A2 (en) 1998-02-12
AU4050797A (en) 1998-02-25
EP0930882A2 (en) 1999-07-28

Similar Documents

Publication Publication Date Title
WO1998005331A3 (en) Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
US20210275504A1 (en) Pharmaceutical compositions for combination therapy
EP0665749B1 (en) Composition for the treatment of parkinson's disease
Millan N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review
TWI407955B (en) A preventive and/or therapeutical agent of hyperlipemia
RS49918B (en) Use of glip-1 or analogs in treatment of myocardial infarction
HUP0301146A2 (en) 2-chlor-5-nitrophenyl carboxamide derivatives, pharmaceutical compositions containing them and their use
CA2581298A1 (en) Combination of dpp-iv inhibitor, ppar antidiabetic and metformin
ES2233931T3 (en) PHENYLACETATE AND DERIVATIVES, ALONE OR IN COMBINATION WITH OTHER COMPOUNDS, AGAINST NEOPLASIC STATES AND OTHER DISORDERS.
KR100949528B1 (en) Combination of a nsaid and a pde-4 inhibitor
HUP0003876A2 (en) Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
KR100597170B1 (en) Riluzole and levodopa combinations for treating parkinson's disease
WO1998048785A3 (en) Allelic polygene diagnosis of reward deficiency syndrome and treatment
HUP0303566A2 (en) Pharmaceutical composition containing combination of fenofibrate and coenzyme q10 and its use for the treatment of endothelial dysfunction
US8865747B2 (en) Pioglitazone for use in the treatment of adrenoleukodystrophy
Cooper Ketoprofen in oral surgery pain: a review
US20130296347A1 (en) Compositions and Methods for Prophylaxis and Treatment of Addictions
US4540582A (en) Treatment of seizure disorders and pharmaceutical compositions useful therein
FI955837A (en) Process for the preparation of an orally administrable solid dosage form containing diclofenac
US6034110A (en) Method for preventing onset of restenosis after angioplasty employing an RXR-specific retinoid and a PPARγ ligand
US4595697A (en) Treatment of seizure disorders and pharmaceutical compositions useful therein
BR9810292A (en) Diabetes treatment with thiazolidinedione, insulin secretagogue and alpha-glucosidase inhibitor
Wallace et al. New generation NSAIDS: The benefits without the risks?
US5545672A (en) Treatment of insulin resistance and type 2 diabetes mellitus with a thiol protease inhibitor
US11241420B2 (en) Compositions and methods for prophylaxis and treatment of addictions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997938101

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998508107

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1997938101

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1997938101

Country of ref document: EP